Similarly, the TYLO analogue DCB-3503 has been shown to inhibit pancreatic cancer cell growth by reducing cell cycle regulatory proteins and inhibiting NF-κB signaling [18]. Here, NFKB1 is linked to pancreatic neoplasm.